Abstract
Background
Ovarian cancer is a gynecologic cancer with a high mortality rate. This shows the need of effective screening methods and reliable cancer markers for ovarian cancer staging and appropriate effective cancer treatment.
Methods
Expression of estrogen receptor α and β was studied by immunhistochemical analysis of 100 ovarian cancer tissue samples.
Results
In this study on 100 serous ovarian cancer tissue samples from patients with defined clinicopathologic features, a significant association of ER-α expression with ovarian cancer grading (p = 0.004), progression-free survival (p = 0.007), and cause-specific survival (p = 0.001) was demonstrated. Expression of ER-β was found to be associated with the metastatic lymph node status (p = 0.006).
Conclusion
Immunohistochemical analysis of ER might be used as an easy, simple and highly efficient marker to identify high-risk patients and may aid in the selection of patients for a more aggressive adjuvant therapy. Furthermore, patients that show a positive ER-α immunostaining can be selected for a specific anti-hormonal therapy, as already performed for breast cancer patients.
Similar content being viewed by others
References
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I (2006) Ovarian cancer. Crit Rev Oncol Hematol 60(2):159–179
Britt KL, Findlay JK (2002) Estrogen actions in the ovary revisited. J Endocrinol 175(2):269–276
Cunat S, Hoffmann P, Pujol P (2004) Estrogens and epithelial ovarian cancer. Gynecol Oncol 94(1):25–32
Rao GG, Miller DS (2006) Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther 6(1):43–47
Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA (2005) Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26(3):465–478
Zhao C, Dahlman-Wright K, Gustafsson JA (2008) Estrogen receptor beta: an overview and update. Nucl Recept Signal 6:e003
Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A (2008) The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 7(9):1460–1467
Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY (2008) Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 111(1):144–151
Geisler JP, Buller E, Manahan KJ (2008) Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol 29(2):126–128
FIGO stages (announcements)1989—revision. Gynecol Oncol 35:125–127
Mylonas I, Jeschke U, Shabani N, Kuhn C, Balle A, Kriegel S, Kupka MS, Friese K (2004) Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem 106(3):245–252
Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS, Friese K (2005) Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 25(3A):1679–1686
Mylonas I, Jeschke U, Shabani N, Kuhn C, Kunze S, Dian D, Friedl C, Kupka MS, Friese K (2007) Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 22(2):169–176
Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H et al (2007) Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43(16):2434–2444
Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen Definierung eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8:138–140
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220
O’Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP (2005) Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 12(4):851–866
Lazennec G (2006) Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 231(2):151–157
Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433
Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM (2007) Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 26(4):404–409
Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK (2007) Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ‘MALOVA’ ovarian cancer study. Oncol Rep 18(5):1051–1059
Acknowledgments
We thank Susanne Kunze and Christina Kuhn for their support in immunohistochemical studies. Additionally, we would also like to thank Prof. D. Hölzel—Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-University Munich and Mr. M. Schmidt of the Munich Tumour Registry for supplying the survival data.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
A. Burges and A. Brüning contributed equally.
Rights and permissions
About this article
Cite this article
Burges, A., Brüning, A., Dannenmann, C. et al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 281, 511–517 (2010). https://doi.org/10.1007/s00404-009-1185-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-009-1185-y